WINSTON PHARMACEUTICALS, INC. Inactive Instrument
Winston Pharmaceuticals, Inc. Stock Other OTC
Equities
WPHM
US9756571074
Pharmaceuticals
| Sales 2008 | 453K 623K | Sales 2009 | 1.39M 1.92M | Capitalization | 21.67M 29.84M |
|---|---|---|---|---|---|
| Net income 2008 | -5M -6.88M | Net income 2009 | -2M -2.75M | EV / Sales 2008 | 572 x |
| Net cash position 2008 | 5.63M 7.75M | Net cash position 2009 | 1.56M 2.15M | EV / Sales 2009 | 14.4 x |
| P/E ratio 2008 |
-49.9
x | P/E ratio 2009 |
-6.46
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 81 | 91-12-31 | |
| Director of Finance/CFO | 57 | - | |
| Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 81 | 91-12-31 |
Winston Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company discovers, develops and commercializes therapeutics for managing and alleviating pain. The Company's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The Company is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The Company's other products are under development for the treatment of headache and neuropathic and rheumatological pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +34.00% | 704B | |
| +25.11% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +14.75% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
